.png)
SummaryGerman packaging law obliges every company that first places filled packaging on the German market, including pharmaceutical manufacturers, importers, wholesalers and pharmacies, to register in the LUCID packaging register before the first shipment, to report packaging volumes, and where household-equivalent packaging is involved to license it with a dual system. From 12 August 2026 this national framework is overlaid by Regulation (EU) 2025/40, the Packaging and Packaging Waste Regulation (PPWR), which applies directly in all Member States and grants specific carve-outs for the immediate packaging of medicinal products.
Most packaging-law guidance is written by packaging consultancies for general e-commerce. That guidance is not wrong, but it is unusable for a pharmaceutical regulatory or supply chain lead, because the pharmaceutical value chain has roles that e-commerce does not have: marketing authorisation holders, parallel importers, full-line wholesalers, hospital pharmacies, and contract manufacturers. It also has product carve-outs that no other sector has. This article sets out what actually applies, by role, and what has to be in place before 12 August 2026.
The German Verpackungsgesetz (VerpackG) entered into force on 1 January 2019 and has been amended substantially since, so any guidance written in 2019 is now materially incomplete. Two changes matter most.
The first is the amending act (VerpackGAendG), in force in stages from 3 July 2021 and 1 July 2022. Before that amendment, the practical registration duty was widely understood as applying to packaging that ends up with private end consumers. Since 1 July 2022 the registration obligation in the LUCID register covers all packaging types, including pure business-to-business transport packaging, reusable packaging, and service packaging filled at the point of handover. The amendment also brought electronic marketplaces and fulfilment service providers into scope: they must verify that their sellers and clients are registered and have joined a system where required.
The second is the PPWR. Regulation (EU) 2025/40 entered into force on 11 February 2025 and applies from 12 August 2026. It is a regulation, not a directive, so it applies directly and does not need transposition. Germany has adapted its national law accordingly through the Verpackungsrecht-Durchfuehrungsgesetz (VerpackDG), which passed the Bundestag on 11 June 2026 and the Bundesrat on 10 July 2026, and which is set to take effect on 12 August 2026 alongside the regulation.
Partly, and this is the point most summaries get wrong. The PPWR replaces Directive 94/62/EC, the directive that the VerpackG implemented. It does not abolish national producer responsibility. What it does is move the substantive product requirements, recyclability, recycled content, minimisation, labelling, to EU level, while leaving Member States to organise registration, extended producer responsibility, collection and deposit systems within a harmonised frame.
In Germany the practical effect is that the VerpackDG largely replaces the VerpackG from 12 August 2026, while carrying over the parts that work: the Zentrale Stelle Verpackungsregister (ZSVR) as the competent register authority, the LUCID register, the dual systems, and the data reporting logic. If you are already registered and licensed correctly, you do not start from zero. If you are not, you now have two legal bases to be wrong about at once.
"The regulation entered into force on 11 February 2025 and applies from 12 August 2026." EUR-Lex summary of Regulation (EU) 2025/40 on packaging and packaging waste.
Only a subset of the PPWR bites on day one. The regulation is deliberately staggered, and confusing the application date with the compliance deadlines for individual product requirements is the most common planning error.
| Requirement | PPWR reference | Applies from |
|---|---|---|
| Regulation applies; Directive 94/62/EC replaced | Final provisions | 12 August 2026 |
| Producer registration and extended producer responsibility obligations in the national register | Art. 44 and following | 12 August 2026 |
| Restriction on PFAS in food contact packaging | Art. 5 | 12 August 2026 |
| Harmonised material and disposal labelling | Art. 12 | 12 August 2028 |
| Design for recycling criteria and recyclability performance grades | Art. 6 | 1 January 2030 |
| Minimum recycled content in plastic packaging | Art. 7 | 1 January 2030 |
| Packaging minimisation and empty space limits | Art. 10 and Art. 24 | 1 January 2030 |
| Reuse and refill targets for transport and grouped packaging | Art. 29 | 1 January 2030 |
The immediate work for August 2026 is therefore administrative, not technical: registration, correct producer identification, correct role classification, and reporting. The technical redesign work has a 2028 to 2030 horizon, which is roughly one full packaging development and stability programme away, so it needs to be started now even though it is not due now.
The PPWR recognises that some packaging cannot be optimised for circularity without compromising product quality, sterility or patient safety. The carve-outs are real, but they are narrower than the industry sometimes assumes.
The critical nuance: the exemptions attach to the packaging function, not to the company. A pharmaceutical manufacturer is not exempt from the PPWR. Its blister, its ampoule, its vial closure system may be exempt from specific product requirements. Its folding carton, its shrink film, its shipper, its pallet wrap and its cold chain shipper are ordinary packaging and carry the ordinary obligations. If the carve-out is being claimed at company level in your compliance file, that file will not survive an audit.
A second nuance is documentation. Claiming an exemption for outer packaging on quality-preservation grounds is a justified claim, which means it has to be justified in writing, product by product, and traceable to the specification. That is a regulatory affairs deliverable, not a procurement one.
Role classification is where pharma-specific complexity concentrates, because a single legal entity often holds several roles at once. A marketing authorisation holder that also imports finished goods and also ships direct to hospitals is a producer three times over in different senses.
| Role | LUCID registration | System participation (dual system) | Data reporting | Typical trap |
|---|---|---|---|---|
| Manufacturer or MAH filling packaging in Germany | Yes, before first placing on market, all packaging types | Yes for household-equivalent packaging, including pharmacy-dispensed cartons | Yes, volumes by material and packaging type | Treating prescription-only status as an exemption. It is not. |
| Importer or parallel importer bringing filled packaging into Germany | Yes, the importer becomes the producer in the packaging-law sense | Yes, for the packaging it first places on the German market | Yes | Assuming the foreign manufacturer has already licensed the packaging. Usually it has not. |
| Foreign manufacturer selling into Germany | Yes, registration is required regardless of establishment; an authorised representative is normally needed | Yes where household-equivalent | Yes | Relying on the German distributor to carry the obligation informally. |
| Full-line wholesaler | Yes, for its own transport, grouped and service packaging | Only for its own household-equivalent packaging, for example direct-to-patient-facing shipments | Yes | Overlooking totes, shrink film, pallet wrap and cold chain shippers as own packaging. |
| Community pharmacy | Yes, as last distributor of service packaging it fills at handover | Yes for service packaging, which can be pre-licensed by the supplier | Reduced where packaging is pre-licensed | Assuming bags and dispensing packaging are out of scope. |
| Hospital pharmacy and institutional supply | Yes, where it fills and hands over packaging | Generally commercial waste rather than household-equivalent, so system participation may not apply | Yes for packaging it places on the market | Unitised repackaging and clinical trial supply are often unmapped entirely. |
| Contract manufacturer or contract packer | Depends on who places the goods on the market under their name | Follows the placing party | Follows the placing party | Contracts silent on who is the producer for packaging-law purposes. |
Section 36 VerpackG sets a tiered framework of administrative fines. The most serious breaches, including operating a system without authorisation, carry fines of up to 200,000 euros. A large group of breaches, including failure to register and failures around placing packaging on the market and deposit obligations, carry fines of up to 100,000 euros. Remaining breaches carry up to 10,000 euros. The commercially relevant sanction, however, is usually not the fine: incomplete registration triggers a distribution ban for the affected packaging, and the LUCID register is public, which makes non-registration visible to competitors and to the ZSVR at the same time.
The packaging-law work depends on data most organisations hold in fragments: which product, which pack size, which packaging components, which market, which legal entity placed it, and which regulatory status applies. Reconciling that across a portfolio and across countries is the part that takes months, not the legal reading.
At pharmazie.com we maintain pharmaceutical product and packaging master data across 25+ databases, covering 50,000+ German products and 120,000+ international products across 50+ countries. That is useful as a reference layer when you are reconciling pack-level data across markets, and it is honestly only one input to a packaging compliance file. The legal classification remains yours.
This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.
